Financials for the half year and year ended 31.03.2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.5 pts less than Nifty Microcap 250 and 5.4 pts less than its Healthcare Services peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Vanta Bioscience Limited submitted its audited financial results for FY25 with a significant delay (approved on August 1, 2025 instead of the May 30, 2025 deadline) due to late receipt of accounts from its associate company. On a standalone basis, revenue from operations collapsed to ₹112.74 lakhs from ₹855.79 lakhs in FY24 (a decline of about 87%), and the company swung from a small profit of ₹5.11 lakhs to a net loss of ₹265.95 lakhs. On a consolidated basis (including subsidiaries Vanta Clinical Research and CEBIS India), revenue fell to ₹196.36 lakhs from ₹972.29 lakhs, and the net loss widened sharply to ₹477.49 lakhs from ₹231.59 lakhs. Total borrowings stood at around ₹3,047 lakhs standalone against equity of ₹1,713 lakhs (debt-equity ratio close to 1.8x), and consolidated debt of about ₹7,008 lakhs against equity of just ₹378 lakhs (very high leverage). Consolidated operating cash flow turned negative at ₹(240.86) lakhs compared to positive ₹268.40 lakhs last year. The statutory auditor (M/s Mathesh & Ramana) gave an unmodified, unqualified opinion, and the company reported no defaults on loans.
This is a negative filing for shareholders — revenue has crashed, losses have deepened, leverage is elevated, and operating cash flow turned negative on a consolidated basis. The delay in filing itself is a compliance red flag, though a clean audit opinion provides some reassurance. Expect weak sentiment around the stock.